New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 11, 2014
07:33 EDTCELGCelgene announces results from long-term Phase III OTEZLA trial
Celgene International SÓrl, a wholly-owned subsidiary of Celgene Corporation, announced results from a long-term phase III trial of OTEZLA, the companyĺs oral, selective inhibitor of phosphodiesterase 4, in psoriatic arthritis patients who have not had prior treatment with systemic or biologic disease-modifying antirheumatic drugs. The data were presented at the European League Against Rheumatism Annual Congress in Paris, France. Results demonstrated that treatment with OTEZLA monotherapy in patients with pre-existing enthesitis or dactylitis, two key manifestations of psoriatic arthritis, resulted in long-term improvements. Results were sustained over 52 weeks in patients initially randomized to OTEZLA monotherapy and completing 52 weeks of the study. At week 52, median Maastricht Ankylosing Spondylitis Enthesitis Scoredecreased by 75.0 percent and 45.9 percent of patients receiving OTEZLA 30 mg BID achieved a score of 0, indicating no pain at any of the enthesitis sites assessed. OTEZLA 30 mg BID also resulted in a median 100 percent decrease in dactylitis count. A dactylitis count of 0, indicating no signs of dactylitis, was achieved in 68.8 percent of patients.
News For CELG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 1, 2015
04:47 EDTCELGStocks with implied volatility movement; CELG XLF
Subscribe for More Information
August 31, 2015
19:27 EDTCELGCelgene initiated with a Strong Buy at Raymond James
Subscribe for More Information
August 28, 2015
07:12 EDTCELGWilliam Blair names 21 stocks best positioned for volatile markets
Subscribe for More Information
August 27, 2015
16:03 EDTCELGCelgene completes acquisition of Receptos
Subscribe for More Information
August 25, 2015
07:31 EDTCELGCelgene announces expiration of tender offer for Receptos shares
Subscribe for More Information
August 24, 2015
18:55 EDTCELGOn The Fly: After Hours Movers
Subscribe for More Information
18:52 EDTCELGJazz, Celgene, Shire up after USPTO rejects Acorda patent challenge
Subscribe for More Information
13:36 EDTCELGBiotech correction presents some opportunities, says RBC Capital
RBC Capital analyst Michael Yee said he won't try to pick the short-term bottom in biotech, but contends that any macro weakness in China shouldn't have any major impact to financials or fundamentals for the sector given their minimal exposure there. If the market continues to be volatile, Yee recommends a focus on names with defensive characteristics, such as higher margins and free cash flow yield, naming Amgen (AMGN), Celgene (CELG) and Gilead (GILD) as some examples. The analyst adds that he likes Vertex (VRTX) on the pullback for "more aggressive" growth investors. Yee has Outperform ratings on all of the stocks mentioned above.
August 23, 2015
12:35 EDTCELGBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use